[go: up one dir, main page]

EP2684948B1 - Procédé pour la production d'anticorps ou de fragments d'anticorps mettant en oeuvre de la levure comprenant un gène vps ayant subi une invalidation génétique - Google Patents

Procédé pour la production d'anticorps ou de fragments d'anticorps mettant en oeuvre de la levure comprenant un gène vps ayant subi une invalidation génétique Download PDF

Info

Publication number
EP2684948B1
EP2684948B1 EP12757313.7A EP12757313A EP2684948B1 EP 2684948 B1 EP2684948 B1 EP 2684948B1 EP 12757313 A EP12757313 A EP 12757313A EP 2684948 B1 EP2684948 B1 EP 2684948B1
Authority
EP
European Patent Office
Prior art keywords
gene
disruption
artificial
dna
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12757313.7A
Other languages
German (de)
English (en)
Other versions
EP2684948A4 (fr
EP2684948A1 (fr
Inventor
Tozo Nishiyama
Yasuyoshi Sakai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of EP2684948A1 publication Critical patent/EP2684948A1/fr
Publication of EP2684948A4 publication Critical patent/EP2684948A4/fr
Application granted granted Critical
Publication of EP2684948B1 publication Critical patent/EP2684948B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Definitions

  • the present invention relates to a method for producing an antibody or an antibody fragment using a yeast host with the improved secretion productivity of a heterologous protein via disruption of at least one vacuolar protein sorting gene (VPS, selected from the group consisting of VPS8, VPS10 and VPS15, and the simultaneous disruption of the vacuolar protease B gene (PBR1 gene).
  • VPS vacuolar protein sorting gene
  • yeasts can be cultured in large-scale, high-density culture systems in cost-effective media, and proteins can be produced at low cost.
  • proteins can be secreted in a culture solution of yeast cells by using a signal peptide or the like, therefore, a process for purifying proteins is easy.
  • VPS vacuolar protein sorting
  • VPS1 to VPS75 While 61 types of VPS genes denoted as VPS1 to VPS75 are known to exist in the budding yeast Saccharomyces cerevisiae, all of such VPS genes are not effective. It is reported that the secretion productivity of a heterologous protein is improved via disruption of the particular VPS gene (Non-Patent Document 1; Patent Documents 1, 2, and 3).
  • genes that are effective to achieve the improved secretion productivity of a heterologous protein vary depending on yeast species.
  • disruption of the VPS10 gene is effective for the fission yeast Schizosaccharomyces pombe (Non-Patent Document 1), although such disruption is not effective for the budding yeast Saccharomyces cerevisiae (Patent Document 1).
  • Non-Patent Document 1 Alimjan, I. Appl. Microbiol. Biotechnol., 2010, vol. 85, pp. 667-677
  • JP 2009 060797 A relates to a method of selecting a heterologous protein secretion highly productive strain.
  • Idiris et al., Appl. Microbiol. Biotechnol. (2010), vol. 85, pp. 667-677 relates to enhanced protein secretion from multiprotease-deficient fission yeast by modification of its vacuolar protein sorting pathway.
  • US 2006/0148039 A1 relates to methylotroph producing mammalian type sugar chain.
  • Morozkina E.V. et al., J. Mol. Microbiol. Biotechnol. (2010), vol. 18, pp. 188-194 describes that proteinase B disruption is required for high level production of human mechano-growth factor in Saccharomyces cerevisiae.
  • WO 2011/053541 A1 relates to methods for the production of recombinant proteins with improved secretion efficiencies.
  • WO 2011/053545 A1 relates to granulocyte-colony stimulating factor produced in glycoengineered Pichia pastoris.
  • US 61/350,668 relates to methods for the production of recombinant proteins with improved secretion efficiencies.
  • Abdel-Salam H. A. et al., Appl. Microbiol. Biotechnol. (2001), vol. 56, pp. 157-164 relates to expression of mouse anticreatine kinase (MAK33) monoclonal antibody in the yeast Hansenula polymorpha.
  • MAK33 mouse anticreatine kinase
  • WO 94/25591 A1 relates to production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of Camelidae.
  • the present invention concerns:
  • the present disclosure provides a method for producing a heterologous protein using a yeast host with the improved secretion productivity of a heterologous protein via disruption of the VPS gene.
  • the "methanol-assimilating yeast" for use in the present invention is the yeast Pichia angusta which can grow with the use of methanol as a sole carbon source.
  • Examples of preferable Pichia angusta strains include, but are not particularly limited to, NCYC495 (ATCC14754), 8V (ATCC34438), and DL-1 (ATCC26012). Such strains can be obtained from the American Type Culture Collection or other institutions. Strains derived from such strains can also be used, and examples of leucine auxotrophs include NCYC495-derived BY4329, 8V-derived BY5242, and DL-1-derived BY5243. These strains can be distributed by the National BioResource Project.
  • strains which can be used, but which are not part of the invention refer to Pichia pastoris strains Y-11430 and X-33. Such strains can be obtained from the Northern Regional Research Laboratory or other institutions. Strains derived from such strains can also be used.
  • Candida boidinii strains NBRC1967, NBRC10035, NBRC10240, NBRC10329, NBRC10574, NBRC10871, NBRC101490, and NBRC101491. These strains can be obtained from the NITE Biological Resource Center or other institutions. Strains derived from such strains can also be used.
  • the "heterologous protein" to be produced by the method of the present invention is an antibody or an antibody fragment.
  • heterologous proteins which can be used are, for example, an enzyme derived from a microorganism or a protein produced by a multicellular organism, such as an animal or plant.
  • a multicellular organism such as an animal or plant.
  • examples thereof include phytase, protein A, protein G, protein L, amylase, glucosidase, cellulase, lipase, protease, glutaminase, peptidase, nuclease, oxidase, lactase, xylanase, trypsin, pectinase, isomerase, and fluorescent protein.
  • Examples include human or animal therapeutic proteins.
  • human or animal therapeutic proteins include hepatitis B virus surface antigen, hirudin, antibody, partial antibody, serum albumin, epidermal growth factor, insulin, growth hormone, erythropoietin, interferon, antihemophilic factor, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), thrombopoietin, IL-1, IL-6, tissue plasminogen activator (TPA), urokinase, leptin, and stem cell growth factor (SCF).
  • G-CSF granulocyte colony-stimulating factor
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • TPA tissue plasminogen activator
  • urokinase urokinase
  • leptin leptin
  • SCF stem cell growth factor
  • antibody refers to a heterotetrameric protein composed of two L- and H-polypeptide chains joined by disulfide bonds.
  • An antibody is not particularly limited, provided that it is capable of binding to a particular antigen.
  • partial antibody refers to Fab antibody, (Fab) 2 antibody, scFv antibody, diabody antibody, or a derivative of any thereof.
  • a partial antibody is not particularly limited, provided that it is capable of binding to a particular antigen.
  • Fab antibody refers to a heteromeric protein comprising the L-chain and the Fd chain of the antibody joined by S-S bonds or a heteromeric protein comprising the L-chain and the Fd chain of the antibody joined with each other without S-S bonds.
  • a Fab antibody is not particularly limited, provided that it is capable of binding to a particular antigen.
  • heterologous protein as mentioned above may originate from any animals without particular limitation. Examples thereof include humans, mice, rats, chickens, and camels. Alternatively, the heterologous protein may be a chimeric protein originating from two or more such animals.
  • a host for secretory production of such heterologous protein can be prepared by transforming the host with a vector for secretory expression of a heterologous protein via genetic engineering.
  • secretory production refers to antibody or antibody fragment accumulation resulting from liquid culture of methanol-assimilating yeast in the culture supernatant instead of the inside of the yeast.
  • Secretory production is carried out by allowing a heterologous protein to express in the form of a fusion protein with a secretory signal, and fusion is realized by, for example, introducing a nucleotide sequence encoding a signal sequence into the 5' end of a nucleotide sequence encoding the heterologous protein.
  • a nucleotide sequence encoding a signal sequence is not particularly limited, provided that the methanol-assimilating yeast Pichia angusta is capable of secreting the heterologous protein.
  • Examples thereof include nucleotide sequences encoding signal sequences of the mating factor ⁇ (MF ⁇ ) of Saccharomyces cerevisiae, acid phosphatase (PHO1) of Pichia angusta , acid phosphatase (PHO1) of Pichia pastoris , invertase (SUC2) of Saccharomyces cerevisiae, PLB1 of Saccharomyces cerevisiae, bovine serum albumin (BSA), human serum albumin (HSA), and immunoglobulin.
  • MF ⁇ mating factor ⁇
  • PHO1 acid phosphatase
  • PHO1 acid phosphatase
  • SUC2 invertase
  • BSA bovine serum albumin
  • HSA human serum albumin
  • host for secretory production refers to a host that can produce heterologous protein at high levels through introduction of an expression vector for secretory production of a heterologous protein thereinto.
  • the host has disruption of the vacuolar protein sorting gene (VPS gene) and has disruption of the vacuolar protease B gene (PRB1 gene) simultaneously with the VPS gene.
  • VPS gene vacuolar protein sorting gene
  • PRB1 gene vacuolar protease B gene
  • expression vector for secretory production of a heterologous protein refers to a nucleic acid molecule having a function of expressing a target gene in a transformed host cell.
  • the expression vector has, for example, an expression cassette, a homologous recombination region, a selection marker gene, such as an auxotrophic complementary gene or drug tolerant gene, and an autonomously replicating sequence.
  • the vector after transformation may be integrated into the chromosome, or it may be present in the form of an autonomously replicating vector.
  • autonomously replicating vectors include the YEp vector, the YRp vector, and the YCp vector.
  • examples of vectors include, but are not particularly limited to, the pPICHOLI, pHIP, pHRP, and pHARS vectors.
  • the "expression cassette" is composed of a promoter and the heterologous protein gene, and it may comprise a terminator gene.
  • a secretory signal may be a signal of the heterologous protein.
  • a secretory signal that can function in a host may be fused to the heterologous protein.
  • the expression cassette can be constructed in, for example, a plasmid such as pUC19, or it can be prepared via PCR.
  • Examples of techniques of yeast transformation include known techniques such as electroporation, the lithium acetate method, and the spheroplast method, although the techniques are not limited thereto.
  • Pichia angusta is generally transformed via electroporation as described in "Highly-efficient electrotransformation of the yeast Hansenula polymorpha " (Curr. Genet., 25: 305.310.).
  • the VPS gene used in the present invention refers to a gene encoding a protein associated with the mechanism of protein transport to the vacuole in a methanol-assimilating yeast, namely at least one gene selected from the group consisting of VPS8, VPS10 and VPS15. More specifically, the term “VPS genes” refers to orthologous genes of the methanol-assimilating yeast corresponding to 61 types of vacuolar protein sorting (VPS) genes denoted as VPS1 to VPS 75 in Saccharomyces cerevisiae.
  • VPS genes refers to orthologous genes of the methanol-assimilating yeast corresponding to 61 types of vacuolar protein sorting (VPS) genes denoted as VPS1 to VPS 75 in Saccharomyces cerevisiae.
  • genes that are defined to encode proteins associated with the mechanism of protein transport to the vacuole in a methanol-assimilating yeast are within the scope of the VPS genes according to the present invention, although such genes do not exist in Saccharomyces cerevisiae.
  • orthologous genes refers to a group of different types of genes, which are evolved from a common progenitor gene and have same functions.
  • the degree of sequence identity between orthologous genes is not particularly limited, provided that the genes are equivalent to each other from the viewpoint of functions and evolutionary development.
  • orthologous genes have 30% or higher, preferably 50% or higher, more preferably 70% or higher, and further preferably 90% or higher sequence identity, at the amino acid level.
  • a single type of VPS gene may be disrupted, or a plurality of VPS genes may be disrupted, provided that the secretion productivity of a heterologous protein is improved.
  • the secretion productivity can be improved by disrupting the VPS gene simultaneously with other genes.
  • genes to be disrupted simultaneously with the VPS gene include genes that encode vacuole protease, such as carboxypeptidase Y, that is abnormally secreted extracellularly upon disruption of the VPS gene. Through disruption of the vacuole protease gene, decomposition of the heterologous protein that had been secreted can be suppressed.
  • vacuole protease such as carboxypeptidase Y
  • the vacuole protease gene refers to the orthologous gene of a methanol-assimilating yeast corresponding to genes of Saccharomyces cerevisiae designated as "PRB1.”
  • Effects for improving secretion productivity can be evaluated by introducing a vector for secretory expression of a heterologous protein into a strain before gene disruption and a gene disruption strain, respectively, culturing the resulting transformed strains under the same conditions (e.g., liquid culture), and comparing the concentrations of heterologous proteins accumulated in a culture supernatant.
  • the total amount of heterologous protein contained in a culture solution is divided by the amount of the yeast cells cultured (i.e., OD or a dry cell weight), and the production amounts of heterologous protein per cell may be compared.
  • gene disruption refers to loss of gene functions or a significant reduction in such functions.
  • VPS gene When the VPS gene is disrupted, for example, the gene product thereof is not expressed at all. Even if the gene product of the VPS gene is expressed, it may not function normally as VPS.
  • Such gene disruption is achieved through modification (i.e., disruption, substitution, addition, or insertion) of nucleotides in an ORF of the gene and/or modification (i.e., disruption, substitution, addition, or insertion) of nucleotides in a region where initiation or termination of transcription is controlled, such as a promoter, enhancer, or terminator region.
  • a site and a sequence subjected to disruption, substitution, addition, or insertion are not particularly limited, provided that normal functions of the gene of interest are deprived.
  • a method for preparing a gene disruption strain is not particularly limited.
  • a vector for gene disruption comprising a partial or full-length VPS gene sequence and a selection marker may be used to introduce the vector into a site in the vicinity of the target VPS gene via homologous recombination.
  • non-homologous recombination or treatment with a mutagen may be performed.
  • the VPS gene to be disrupted is at least one gene selected from the VPS8, VPS10, and VPS15 gene.
  • One of the above VPS genes may be subjected to disruption alone or two or more thereof may be subjected to disruption in combination.
  • An example of a method for antibody or antibody fragment secretion using the host for secretory production of the present invention is a method comprising culturing the host for secretory production and allowing heterologous proteins to accumulate in the culture supernatant.
  • a host for secretory production can be generally cultured with the use of any medium containing a nutrient source that can be utilized by a methanol-assimilating yeast.
  • a common medium obtained by adequately mixing carbon sources such as sugars (e.g., glucose, sucrose, and maltose), organic acids (e.g., lactic acid, acetic acid, citric acid, and propionic acid), alcohols (e.g., methanol, ethanol, and glycerol), carbohydrates (e.g., paraffin), fats and oils (e.g., soybean oil and rapeseed oil), or mixtures of any thereof, nitrogen sources, such as ammonium sulfate, ammonium phosphate, urea, yeast extract, meat extract, peptone, and corn steep liquor, and other nutrient sources, such as inorganic salts and vitamins, can be used, and culture can be carried out in a batch or continuous system.
  • carbon sources such as sugars (e.g., glucose, sucrose, and maltose), organic acids (e.g., lactic acid, acetic acid, citric acid, and propionic acid), alcohols (e.g., m
  • An antibody or antibody fragment produced with the use of the host for secretory production according to the present invention may be present in a culture supernatant, or a protein may be isolated therefrom via any technique.
  • the protein can be isolated from a culture supernatant by performing known protein purification techniques in adequate combination.
  • the host for secretory production is first cultured in an adequate medium, and a culture solution is subjected to centrifugation or filtration to remove yeast from the culture supernatant.
  • the obtained culture supernatant is then subjected to techniques such as salting-out (e.g., ammonium sulfate precipitation or sodium phosphate precipitation), solvent precipitation (e.g., protein fractional precipitation with acetone or ethanol), dialysis, gel filtration chromatography, ion-exchange chromatography, hydrophobic chromatography, affinity chromatography, reverse phase chromatography, or ultrafiltration. Any such techniques may be carried out alone or in combination, and the heterologous protein of the present invention is isolated from the culture supernatant.
  • salting-out e.g., ammonium sulfate precipitation or sodium phosphate precipitation
  • solvent precipitation e.g., protein fractional precipitation with acetone or ethanol
  • dialysis gel filtration chromatography, ion
  • the isolated antibody or antibody fragment can be used without processing.
  • such antibody or antibody fragment may be subjected to pharmacological modification such as PEGylation, modification for the purpose of impartation of enzyme or isotope functions, or other types of modification before use.
  • proteins may be used in various forms of formulations.
  • Plasmids obtained in the examples below were amplified using transformants obtained with the use of E . coli DH5 ⁇ competent cells (Takara Bio Inc.) under the designated conditions.
  • PCR was carried out using the Prime STAR HS DNA Polymerase (Takara Bio Inc.) in accordance with the manufacturer's instructions. Genomic DNAs were prepared from yeasts using Dr. GenTLE® (Takara Bio Inc.) in accordance with the manufacturer's instructions.
  • the MOX promoter (SEQ ID NO: 1), the MOX terminator (SEQ ID NO: 2), the LEU2 gene (SEQ ID NO: 3), and the GAP promoter (SEQ ID NO: 4) used when constructing the antibody-expressing vector and the vector for VPS gene disruption were prepared by PCR using genomic DNA of the Pichia angusta 8V strain as the template.
  • the mating factor ⁇ pre-pro signal gene (MF ⁇ , SEQ ID NO: 5) was prepared by PCR using genomic DNA of Saccharomyces cerevisiae S288c as a template.
  • the antibody gene was prepared by PCR using, as templates, the L-chain gene (SEQ ID NO: 6) and the H-chain gene (SEQ ID NO: 7) chemically synthesized based on the disclosed sequence information of the fully humanized anti-TNF-a antibody (adalimumab; HUMIRA®) ( JP 2009-082033 A ).
  • the G418 tolerant gene (SEQ ID NO: 8) was prepared by PCR using, as a template, pMW218 (Nippon Gene).
  • the zeocin tolerant gene (SEQ ID NO: 52) was prepared by PCR using, as a template, pPICZ ⁇ (Invitrogen).
  • the VPS8 gene (SEQ ID NO: 9), the VPS10 gene (SEQ ID NO: 10), the VPS15 gene (SEQ ID NO: 11), the VPS17 gene (SEQ ID NO: 12), the VPS21 gene (SEQ ID NO: 13), the VPS26 gene (SEQ ID NO: 14), the VPS45 gene (SEQ ID NO: 15), and the PRB1 gene (SEQ ID NO: 53) were prepared by PCR using, as a template, genomic DNA of the Pichia angusta NCYC495 strain.
  • a gene fragment (SEQ ID NO: 16) having the Hind III- Not I- Bam HI -Spe I -Mun I -Bgl II- Xba I- Eco RI sites was fully synthesized, and the resultant was inserted into the Hin dIII and Eco RI sites of pUC19 to prepare pUC-1.
  • a gene fragment having the Hin dIII sites on both sides of the LEU2 was prepared by PCR using the primers 1 and 2 (SEQ ID NOs: 17 and 18), the fragment was treated with Hin dIII, and it was then inserted into the Hin dIII site of pUC-1 to prepare pUC-2.
  • a gene fragment having the BamHI sites on both sides of the MOX promoter was prepared by PCR using the primers 3 and 4 (SEQ ID NOs: 19 and 20), the fragment was treated with BamHI, and it was then inserted into the Bam HI site of pUC-2 to prepare pUC-3.
  • a gene fragment having the Mun I sites on both sides of the MOX promoter was prepared by PCR using the primers 5 and 6 (SEQ ID NOs: 21 and 22), the fragment was treated with Mun I, and it was then inserted into the Mun I site of pUC-3 to prepare pUC-4.
  • a gene fragment having the Xba I site on both sides of the MOX terminator was prepared by PCR using the primers 7 and 8 (SEQ ID NOs: 23 and 24), the fragment was treated with Xba I, and it was then inserted into the Xba I site of pUC-4 to prepare pUC-PmPmTm.
  • a gene fragment having the SpeI site in a site upstream of MFa was prepared by PCR using the primers 9 and 10 (SEQ ID NOs: 25 and 26).
  • a gene fragment having a 20-bp 3'-terminal fragment of MFa in a site upstream of the L-chain and the Spe I site in a site downstream of the L-chain was prepared by PCR using the primers 11 and 12 (SEQ ID NOs: 27 and 28). These gene fragments were mixed to prepare a template, and PCR was carried out using the resulting template and the primers 9 and 12 to prepare a gene fragment having the Spe I sites on both sides of a fusion gene of MFa and the L-chain. The resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-PmPmTm to prepare pUC-PmLPmTm.
  • a gene fragment having the Bgl II site in a site upstream of MFa was prepared by PCR using the primer 13 (SEQ ID NO: 29) and the primer 10.
  • a gene fragment having a 20-bp 3'-terminal fragment of MFa in a site upstream of the Fd-chain and the Bgl II site in a site downstream of the Fd-chain was prepared by PCR using the primers 14 and 15 (SEQ ID NOs: 30 and 31). These gene fragments were mixed to prepare a template, and PCR was carried out using the resulting template and the primers 13 and 15 to prepare a gene fragment having the Bgl II sites on both sides of a fusion gene of MFa and the Fd-chain.
  • the resulting gene fragment was treated with Bgl II and inserted into the Bgl II site of pUC-PmLPmTm to prepare pUC-PmLPmFTm.
  • This expression vector is designed to allow expression of the L-chain and the Fd-chain of the Fab antibody under the control of the different MOX promoters.
  • the Fab antibody-expressing vector prepared in Example 1 was cleaved at the EcoRV or Nru I site in the MOX terminator gene to prepare a linearized fragment, and Pichia angusta was transformed using the resulting fragment. Transformation was carried out as described below.
  • Pichia angusta BY4329 cells (NCYC495-derived, leu1-1) were inoculated into 3 ml of YPD medium (1% Bacto Yeast Extract (Difco), 2% Bacto Tryptone (Difco), and 2% glucose) and subjected to shake culture at 37°C overnight to obtain a pre-culture solution.
  • the obtained pre-culture solution 500 ⁇ l was inoculated into 50 ml of YPD medium, shake culture was conducted at 30°C until OD 600 reached 1 to 1.5, and the culture product was centrifuged at 3,000 x g and 20°C for 10 minutes to harvest cells.
  • the cells were suspended in 10 ml of 50 mM potassium phosphate buffer (pH 7.5) containing 250 ⁇ l of 1M DTT (final concentration: 25 mM), and the suspension was incubated at 37°C for 15 minutes. After the cells were harvested by centrifugation at 3,000 x g and 4°C for 10 minutes, the cells were resuspended in 50 ml of ice-cooled STM buffer (270 mM sucrose, 10 mM Tris-HCl, and 1 mM magnesium chloride; pH 7.5). After the cells were harvested by centrifugation at 3,000 x g and 4°C for 10 minutes, the cells were resuspended in 25 ml of ice-cooled STM buffer. After the cells were harvested by centrifugation at 3,000 x g and 4°C for 10 minutes, the cells were suspended in 250 ⁇ l of ice-cooled STM buffer, and the resulting suspension was designated as a competent cell solution.
  • 50 mM potassium phosphate buffer
  • the competent cell solution (60 ⁇ l) was mixed with 3 ⁇ l of a solution of linearized Fab antibody-expressing vector (the amount of DNA: 0.5 to 1 ⁇ g), and the mixture was transferred into an electroporation cuvette (a disposable cuvette; electrode gap: 2 mm; BM Equipment Co., Ltd.) and subjected to electroporation at 7.5 kV/cm, 10 ⁇ F, and 900 ⁇ . Thereafter, cells were suspended in 1 ml of YPD medium, and the suspension was then allowed to stand at 37°C for 1 hour.
  • electroporation cuvette a disposable cuvette; electrode gap: 2 mm; BM Equipment Co., Ltd.
  • Fab antibody-expressing strains were obtained.
  • a fragment having the SpeI sites in sites upstream and downstream of a sequence of nucleotides 989 to 3395 of the VPS8 ORF (SEQ ID NO: 9) was prepared by PCR using primers 16 and 17 (SEQ ID NOs: 32 and 33). The resulting gene fragment was treated with SpeI and inserted into the Spe I site of pUC-1 to prepare pUC-VPS8.
  • a fragment having the Hin dIII site in a site upstream of the GAP promoter and the 5'-terminal sequence of the G418 tolerant gene in a site downstream of the GAP promoter was prepared by PCR using primers 18 and 19 (SEQ ID NOs: 34 and 35).
  • a fragment having the Hin dIII site in a site downstream of the G418 tolerant gene was prepared by PCR using primers 20 and 21 (SEQ ID NOs: 36 and 37). With the use of these two fragments as templates and primers 18 and 21, PCR was carried out to obtain a fragment having the Hin dIII sites in sites upstream and downstream of the G418 tolerant gene under the control of the GAP promoter.
  • the G418 tolerant gene was inserted into the Hin dIII site in the VPS8 gene of pUC-VPS8 to prepare pUC- ⁇ vps8.
  • pUC- ⁇ vps8 was treated with Spe I to construct a vector for VPS8 gene disruption having the G418 tolerant gene inserted into the Hin dIII site of the sequence comprising nucleotides 989 to 3395 of the VPS8 gene.
  • the resulting vector for VPS8 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2, and colonies were selected on the YNB plate containing G418 at 0.5 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the VPS8 gene, and the Fab antibody-expressing strain with disruption of the VPS8 gene was obtained.
  • a fragment having the Spe I sites in sites upstream and downstream of a sequence of nucleotides 3029 to 4484 of the VPS10 ORF (SEQ ID NO: 10) was prepared by PCR using primers 22 and 23 (SEQ ID NOs: 38 and 39). The resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-1 to prepare pUC-VPS10.
  • a fragment having the Bsp1407I site in a site upstream of the GAP promoter and the 5'-terminal sequence of the G418 tolerant gene in a site downstream of the GAP promoter was prepared by PCR using the primer 24 (SEQ ID NO: 40) and the primer 19.
  • a fragment having the Bsp1407I site in a site downstream of G418 tolerant gene was prepared by PCR using the primer 20 and the primer 25 (SEQ ID NO: 41). With the use of these two fragments as templates and primers 24 and 25, PCR was carried out to obtain a fragment having the Bsp1407I sites in sites upstream and downstream of the G418 tolerant gene under the control of the GAP promoter.
  • the G418 tolerant gene was inserted into the Bsp1407I site in the VPS10 gene of pUC-VPS10 to prepare pUC- ⁇ vps10.
  • pUC- ⁇ vps10 was treated with Spe I to construct a vector for VPS10 gene disruption comprising the G418 tolerant gene inserted into the Bsp1407I site of the sequence comprising nucleotides 3029 to 4484 of the VPS10 gene.
  • the resulting vector for VPS10 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2, and colonies were selected on the YNB plate containing G418 at 0.5 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the VPS10 gene, and the Fab antibody-expressing strain with disruption of the VPS10 gene was obtained.
  • a fragment having the Spe I sites in sites upstream and downstream of a sequence of nucleotides 506 to 2112 of the VPS15 ORF (SEQ ID NO: 11) was prepared by PCR using primers 26 and 27 (SEQ ID NOs: 42 and 43). The resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-1 to prepare pUC-VPS15.
  • the G418 tolerant gene prepared in Example 4 was inserted into the Bsp1407I site in the VPS15 gene of pUC-VPS15 to prepare pUC- ⁇ vps15.
  • pUC- ⁇ vps15 was treated with SpeI to construct a vector for VPS15 gene disruption comprising the G418 tolerant gene inserted into the Bsp1407I site of the sequence comprising nucleotides 506 to 2112 of the VPS15 gene.
  • the resulting vector for VPS15 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2, and colonies were selected on the YNB plate containing G418 at 0.5 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the VPS15 gene, and the Fab antibody-expressing strain with disruption of the VPS 15 gene was obtained.
  • a fragment having the Spe I sites in sites upstream and downstream of a sequence of nucleotides 106 to 1512 of the VPS17 ORF (SEQ ID NO: 12) was prepared by PCR using primers 28 and 29 (SEQ ID NOs: 44 and 45). The resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-1 to prepare pUC-VPS17.
  • the G418 tolerant gene prepared in Example 4 was inserted into the Bsp1407I site in the VPS17 gene of pUC-VPS17 to prepare pUC- ⁇ vps17.
  • pUC- ⁇ vps17 was treated with Spe I to construct a vector for VPS17 gene disruption comprising the G418 tolerant gene inserted into the Bsp1407I site of the sequence comprising nucleotides 106 to 1512 of the VPS17 gene.
  • the resulting vector for VPS17 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2, and colonies were selected on the YNB plate containing G418 at 0.5 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the VPS17 gene, and the Fab antibody-expressing strain with disruption of the VPS17 gene was obtained.
  • a fragment having the Spe I sites in sites upstream and downstream of a sequence of nucleotides 31 to 605 of the VPS21 ORF (SEQ ID NO: 13) was prepared by PCR using primers 30 and 31 (SEQ ID NOs: 46 and 47). The resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-1 to prepare pUC-VPS21.
  • the G418 tolerant gene prepared in Example 3 was inserted into the Hin dIII site in the VPS21 gene of pUC-VPS21 to obtain pUC- ⁇ vps21.
  • pUC- ⁇ vps21 was treated with Spe I to construct a vector for VPS21 gene disruption comprising the G418 tolerant gene inserted into the Hin dIII site of the sequence comprising nucleotides 31 to 605 of the VPS21 gene.
  • the resulting vector for VPS21 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2, and colonies were selected on the YNB plate containing G418 at 0.5 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the VPS21 gene, and the Fab antibody-expressing strain with disruption of the VPS21 gene was obtained.
  • a fragment having the Spe I sites in sites upstream and downstream of a sequence of nucleotides 31 to 882 of the VPS26 ORF (SEQ ID NO: 14) was prepared by PCR using primers 32 and 33 (SEQ ID NOs: 48 and 49). The resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-1 to prepare pUC-VPS26.
  • the G418 tolerant gene under the control of the GAP promoter prepared in Example 4 was inserted into the Bsp1407I site in the VPS26 gene of pUC-VPS26 to prepare pUC- ⁇ vps26.
  • pUC- ⁇ vps26 was treated with Spe I to construct a vector for VPS26 gene disruption comprising the G418 tolerant gene inserted into the Bsp1407I site of the sequence comprising nucleotides 31 to 882 of the VPS26 gene.
  • the resulting vector for VPS26 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2, and colonies were selected on the YNB plate containing G418 at 0.5 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the VPS26 gene, and the Fab antibody-expressing strain with disruption of the VPS26 gene was obtained.
  • a fragment having the Spe I sites in sites upstream and downstream of a sequence of nucleotides 647 to 1697 of the VPS45 ORF (SEQ ID NO: 15) was prepared by PCR using primers 34 and 35 (SEQ ID NOs: 50 and 51). The resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-1 to prepare pUC-VPS45.
  • the G418 tolerant gene prepared in Example 4 under the control of the GAP promoter was inserted into the Bsp1407I site in the VPS45 gene of pUC-VPS45 to prepare pUC- ⁇ vps45.
  • pUC- ⁇ vps45 was treated with Spe I to construct a vector for VPS45 gene disruption comprising the G418 tolerant gene inserted into the Bsp1407I site of the sequence comprising nucleotides 647 to 1697 of the VPS45 gene.
  • the resulting vector for VPS45 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2, and colonies were selected on the YNB plate containing G418 at 0.5 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the VPS45 gene, and the Fab antibody-expressing strain with disruption of the VPS45 gene was obtained.
  • a fragment having the Spe I sites in sites upstream and downstream of a sequence of nucleotides 51 to 1400 of the PRB1 ORF (SEQ ID NO: 53) was prepared by PCR using primers 36 and 37 (SEQ ID NOs: 54 and 55). The resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-1 to prepare pUC-PRB1.
  • a zeocin tolerant gene fragment was prepared by PCR using primers 38 and 39 (SEQ ID NOs: 56 and 57).
  • the zeocin tolerant gene fragment prepared above was inserted into the EcoRV site in the PRB1 gene of pUC-PRB1 to prepare pUC- ⁇ prb1.
  • pUC- ⁇ prb1 was treated with Spe I to construct a vector for PRB1 gene disruption comprising the zeocin tolerant gene inserted into the EcoRV site of the sequence comprising nucleotides 51 to 1400 of the PRB1 gene.
  • the resulting vector for PRB1 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2 and the Fab antibody-expressing strains with disruption of the VPS (VPS8, VPS10, and VPS15) genes described in Examples 3 to 5, and colonies were selected on the YNB plate containing zeocin at 0.1 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the PRB1 gene, and the Fab antibody-expressing strain with disruption of the PRB1 gene and the Fab antibody-expressing strain with double disruption of the PRB1 and VPS genes were obtained.
  • a fragment having the Spe I sites in sites upstream and downstream of a sequence of nucleotides 51 to 1000 of the PEP4 ORF (SEQ ID NO: 58) was prepared by PCR using primers 40 and 41 (SEQ ID NOs: 59 and 60) and genomic DNA of the Pichia angusta NCYC495 strain as the template.
  • the resulting gene fragment was treated with Spe I and inserted into the SpeI site of pUC-1 to prepare pUC-PEP4.
  • the zeocin tolerant gene fragment prepared in Example 10 was inserted into the Sca I site in the PEP4 gene of pUC-PEP4 to prepare pUC- ⁇ pep4.
  • pUC- ⁇ pep4 was treated with Spe I to construct a gene for PEP4 gene disruption comprising the zeocin tolerant gene inserted into the Sca I site of the sequence comprising nucleotides 51 to 1400 of the PEP4 gene.
  • the resulting vector for PEP4 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2 and the Fab antibody-expressing strains with disruption of the VPS (VPS8, VPS10, and VPS15) genes described in Examples 3 to 5, and colonies were selected on the YNB plate containing zeocin at 0.1 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the PEP4 gene, and the Fab antibody-expressing strain with disruption of the PEP4 gene and the Fab antibody-expressing strain with double disruption of the PEP4 and VPS genes were obtained.
  • a fragment having the SpeI sites in sites upstream and downstream of a sequence of nucleotides 501 to 1700 of the YPS1 ORF (SEQ ID NO: 61) was prepared by PCR using primers 42 and 43 (SEQ ID NOs: 62 and 63) and genomic DNA of the Pichia angusta NCYC495 strain as the template.
  • the resulting gene fragment was treated with Spe I and inserted into the Spe I site of pUC-1 to prepare pUC-YPS1.
  • the zeocin tolerant gene fragment prepared in Example 10 was inserted into the EcoRV site in the YPS1 gene of pUC-YPS1 to prepare pUC- ⁇ yps1.
  • pUC- ⁇ yps1 was treated with Spe I to construct a vector for YPS1 gene disruption comprising the zeocin tolerant gene inserted into the EcoRV site of the sequence comprising nucleotides 501 to 1700 of the YPS1 gene.
  • the resulting vector for YPS1 gene disruption was used to transform the Fab antibody-expressing strain described in Example 2 and the Fab antibody-expressing strain with disruption of the VPS (VPS10) gene described in Example 4, and colonies were selected on the YNB plate containing zeocin at 0.1 g/l. PCR was carried out to confirm that the vector for gene disruption had been inserted into the YPS1 gene, and the Fab antibody-expressing strain with disruption of the YPS1 gene and the Fab antibody-expressing strain with double disruption of the YPS1 and VPS genes were obtained.
  • VPS gene disruption strains and the double-disruption strains of the VPS and PRB1 genes obtained in Examples 3 to 10 and original strains (undisrupted strains) used for preparation of these gene disruption strains were subjected to sandwich ELISA (enzyme-linked immunosorbent assay) to analyze the amount of Fab antibodies secreted in the culture supernatant.
  • the culture supernatant was prepared in the manner described below. Specifically, Fab antibody-expressing strains were inoculated into 2 ml of BMGMY medium (1% Bacto Yeast Extract, 2% peptone, 1.34% yeast nitrogen base, 0.4 mg/l biotin, 100 mM potassium phosphate (pH 6.0), 1% glycerol, and 1% methanol), shake culture was performed at 30°C for 72 hours, and the culture supernatant was prepared by centrifugation at 15,000 rpm and 4°C for 1 minute.
  • BMGMY medium 1% Bacto Yeast Extract, 2% peptone, 1.34% yeast nitrogen base, 0.4 mg/l biotin, 100 mM potassium phosphate (pH 6.0), 1% glycerol, and 1% methanol
  • Sandwich ELISA was performed in the manner described below.
  • an immobilization buffer a 0.1 N sodium bicarbonate solution; pH 9.6
  • PBST PBS (Takara Bio Inc.) + 0.1% Tween 20
  • serial dilutions of the standard proteins anti-human IgG Fab, Rockland
  • the diluted culture supernatant were added at 50 ⁇ l/well, and the reaction was allowed to proceed at room temperature for 1 hour.
  • the solution was removed from the wells, the wells were washed two times with PBST, a secondary antibody solution diluted 8,000-fold with a PBSTIB (PBST + 1/50-diluted Immunoblock) solution (secondary antibody: Anti-human IgG (Fab-specific)-peroxidase conjugate antibody developed in goat affinity isolated antibody, SIGMA) was added at 50 ⁇ l/well, and the reaction was allowed to proceed at room temperature for 1 hour.
  • PBSTIB PBST + 1/50-diluted Immunoblock
  • the solution was removed from the wells, the wells were washed four times with PBST, the SureBlue TMB 1-component microwell peroxidase substrate (KPL) was added at 100 ⁇ l/well, and the reaction solution was allowed to stand at room temperature for 20 minutes. The reaction was terminated with the addition of the TMB stop solution (KPL) at 100 ⁇ l/well, and the absorbance at 450 nm was then measured using a microplate reader (BenchMark Plus, Bio-Rad). The antibodies in the culture supernatant were quantified using the calibration curve for the standard protein. Thus, accumulation of antibodies secreted in the culture supernatant was confirmed.
  • KPL microwell peroxidase substrate
  • the PEP4 gene disruption strain obtained in Comparative Example 1 and the YPS1 gene disruption strain obtained in Comparative Example 2 were inspected in the same manner concerning the amount of antibodies secreted in the culture supernatant.
  • Table 1 Strain Fab (mg/l) Undisrupted strain 4.6 VPS8-disruption strain (Example 3) 6.3 VPS10-disruption strain (Example 4) 6.2 VPS15-disruption strain (Example 5) 6.1 VPS17-disruption strain (Example 6) 5.6 VPS21-disruption strain (Example 7) 5.4 VPS26-disruption strain (Example 8) 5.2 VPS45-disruption strain (Example 9) 4.8 Table 2 Strain Fab (mg/l) PRB1-disruption strain (Example 10) 4.1 PRB1/VPS8 double-disruption strain (Example 10) 8.6 PRB1/VPS10 double-disruption strain (Example 10) 10.3 PRB1/VPS15 double-disruption strain (Example 10) 9.1 P
  • the amount of Fab secretion increased as a result of disruption of the VPS gene. As shown in Table 2, the amount of Fab secretion further increased as a result of double-disruption of the VPS and PRB1 genes. In the case of double-disruption of the VPS and PEP4 genes or the VPS and YPS1 genes, however, the amount of Fab secretion did not increase any more.
  • the present invention can be used in the field of production of antibodies or antibody fragments used for treatment of diseases.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (1)

  1. Procédé de production d'un anticorps ou d'un fragment d'anticorps, caractérisé en ce qu'il comprend l'utilisation de Pichia angusta avec une interruption du gène de tri protéique vacuolaire (gène VPS) et avec une interruption du gène de protéase B vacuolaire (gène PRB1) simultanément avec le gène VPS en tant qu'hôte pour la production sécrétoire de l'anticorps ou du fragment d'anticorps, dans lequel le gène VPS est au moins un gène sélectionné dans le groupe consistant en VPS8, VPS10, et VPS15.
EP12757313.7A 2011-03-11 2012-03-07 Procédé pour la production d'anticorps ou de fragments d'anticorps mettant en oeuvre de la levure comprenant un gène vps ayant subi une invalidation génétique Active EP2684948B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011054637 2011-03-11
PCT/JP2012/055825 WO2012124567A1 (fr) 2011-03-11 2012-03-07 Procédé pour la production de protéine hétérologue mettant en œuvre de la levure comprenant un gène vps ayant subi une invalidation génétique

Publications (3)

Publication Number Publication Date
EP2684948A1 EP2684948A1 (fr) 2014-01-15
EP2684948A4 EP2684948A4 (fr) 2014-10-22
EP2684948B1 true EP2684948B1 (fr) 2019-12-04

Family

ID=46830640

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12757313.7A Active EP2684948B1 (fr) 2011-03-11 2012-03-07 Procédé pour la production d'anticorps ou de fragments d'anticorps mettant en oeuvre de la levure comprenant un gène vps ayant subi une invalidation génétique

Country Status (4)

Country Link
US (1) US9102969B2 (fr)
EP (1) EP2684948B1 (fr)
JP (1) JP5932766B2 (fr)
WO (1) WO2012124567A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015004241A2 (fr) 2013-07-10 2015-01-15 Novartis Ag Cellules fongiques filamenteuses déficientes en plusieurs protéases et procédés d'utilisation de celles-ci
CA2954974A1 (fr) 2014-07-21 2016-01-28 Glykos Finland Oy Production de glycoproteines avec des n-glycanes de type mammifere dans des champignons filamenteux
CN104212729B (zh) * 2014-09-16 2017-03-15 天津科技大学 耐高糖面包酵母菌株的构建及其选育方法
CN108473542B (zh) * 2015-10-26 2023-05-09 科学与工业研究委员会 遗传修饰的酵母细胞和改进的用于生产凝块特异性链激酶的方法
US10355893B2 (en) 2017-10-02 2019-07-16 Micron Technology, Inc. Multiplexing distinct signals on a single pin of a memory device
SE2051317A1 (en) * 2020-11-11 2022-05-12 Nielsen Dina Petranovic A genetically modified yeast cell
CN113862242B (zh) * 2021-10-15 2024-06-25 江南大学 一种减弱液泡分选提高里氏木霉纤维素酶产量的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025591A1 (fr) * 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION D'ANTICORPS OU DE FRAGMENTS FONCTIONNALISES D'ANTICORPS, DERIVES DES IMMUNOGLOBULINES A CHAINE LOURDE DE $i(CAMELIDAE)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60325720D1 (de) 2002-04-26 2009-02-26 Kirin Pharma Kk Methylotrophe hefe,die eine zuckerkette eines säugers herstellt
JP2009060797A (ja) 2007-09-04 2009-03-26 National Research Inst Of Brewing 異種タンパク質分泌高生産株を選抜する方法
JP2009082033A (ja) 2007-09-28 2009-04-23 Kaneka Corp 完全ヒト型抗体生産法
JP2009240185A (ja) 2008-03-28 2009-10-22 Toyota Central R&D Labs Inc 外来性タンパク質の高生産形質転換体及びその利用
JP2010193869A (ja) 2009-01-30 2010-09-09 Toyota Central R&D Labs Inc 外来性タンパク質の高生産形質転換体及びその利用
EP2494050A4 (fr) * 2009-10-30 2013-10-30 Merck Sharp & Dohme Facteur de stimulation des granulocytes et monocytes produit dans pichia pastoris glycomodifié
MX2012004993A (es) * 2009-10-30 2012-06-12 Merck Sharp & Dohme Metodos para la produccion de proteinas recombinantes con eficiencias de secrecion mejoradas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025591A1 (fr) * 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION D'ANTICORPS OU DE FRAGMENTS FONCTIONNALISES D'ANTICORPS, DERIVES DES IMMUNOGLOBULINES A CHAINE LOURDE DE $i(CAMELIDAE)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOUSUKE KURODA ET AL: "Antibody expression in protease-defficient strains of the methylotrophic yeast Ogataea minuta", FEMS YEAST RES., WILEY-BLACKWELL PUBLISHING LTD, GB, NL, vol. 7, no. 8, 1 December 2007 (2007-12-01), pages 1307 - 1316, XP008127158, ISSN: 1567-1356, [retrieved on 20070823], DOI: 10.1111/J.1567-1364.2007.00291.X *

Also Published As

Publication number Publication date
EP2684948A4 (fr) 2014-10-22
JP5932766B2 (ja) 2016-06-08
US20140106404A1 (en) 2014-04-17
JPWO2012124567A1 (ja) 2014-07-24
US9102969B2 (en) 2015-08-11
WO2012124567A1 (fr) 2012-09-20
EP2684948A1 (fr) 2014-01-15

Similar Documents

Publication Publication Date Title
EP2684948B1 (fr) Procédé pour la production d'anticorps ou de fragments d'anticorps mettant en oeuvre de la levure comprenant un gène vps ayant subi une invalidation génétique
EP2669375B1 (fr) Levure du genre, pichia, modifiée pour exprimer un niveau élevé d'un homologue de mpp1 et procédé de production d'une protéine
CN105229154A (zh) 组成型启动子
CN113423836B (zh) 重组宿主细胞中碳源调节的蛋白的产生
CN105121652A (zh) 用于在酵母和其它转化细胞中高产量表达多肽的温度变动法
JP6138788B2 (ja) 形質転換した微生物、例えばピキア・パストリス中で抗体などのマルチサブユニットタンパク質を高濃度かつ高純度で生産するための多コピー法
CN108699151A (zh) 用于制备免疫球蛋白单可变结构域的方法
EP2990485B1 (fr) Gene de chaine fd ou gene de chaine l chacun apte a augmenter la quantite de secretion d'anticorps de type fab
US11485979B2 (en) Cell and method for producing target protein using same
US20190010194A1 (en) Methanol-utilizing yeast-derived novel protein and method for producing protein of interest using same
JP2016146789A (ja) 新規オガタエア属酵母及びそれを用いた異種タンパク質の製造方法。
JP7239205B2 (ja) 新規宿主細胞及びそれを用いた目的タンパク質の製造方法
US11365419B2 (en) Host cell and method for producing target protein using same
EP3015549B1 (fr) Nouveau polypeptide, et application de celui-ci
EP3015548B1 (fr) Nouveau polypeptide, et application de celui-ci
Stasyk et al. in the Methylotrophic Yeasts

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130917

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140924

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101ALI20140918BHEP

Ipc: C12N 1/19 20060101AFI20140918BHEP

Ipc: C12P 21/08 20060101ALI20140918BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180628

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190416

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190725

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1209425

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012066205

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191204

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200304

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200304

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200404

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012066205

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1209425

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191204

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20200907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200307

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250128

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250210

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250130

Year of fee payment: 14